Santhera Pharmaceuticals suffered a setback today with the rejection of its key experimental drug for a genetic cause of blindness. European Union reviewers denied the Swiss specialty pharma their support for approval of Raxone over concerns about the small number of patients studied during clinical development.
French drugmaker Ipsen ($IPN) has a game plan for developing new drugs, and Santhera's ($SANN) Parkinson's disease treatment fipamezole didn't make the cut. Switzerland-based Santhera said that it
Santhera Pharmaceuticals and Ipsen have inked an agreement for fipamezole, which is being studied to treat levodopa-induced dyskinesia in Parkinson's disease. Under the terms of the agreement,
Switzerland's Santhera Pharmaceuticals (SANN) says its lead drug failed a late-stage trial. And the news triggered a sharp, 31 percent drop in the developer's stock. Even though CEO Klaus Schollmeier
Shares of Switzerland's Santhera Pharmaceuticals got a boost this morning after the developer announced a $192 million licensing pact with Biovail for its experimental drug for dyskinesia in
Swiss drugmaker Santhera announced today that it is cutting its drug discovery efforts in order to give the company enough cash to survive until its lead drug Catena is approved in the US and Europe.
Switzerland's Santhera Pharmaceuticals took a turn at the stock market's whipping post this morning after announcing that its lead drug missed its primary endpoint in a late-stage study. Its shares